Skip to content

Oxygen Toxicity of HBOT in Chronic Brain Injury

Oxygen Toxicity Effects Using Los-Pressure Hyperbaric Oxygen Therapy in the Treatment of Chronic Brain Injury

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00592891
Enrollment
45
Registered
2008-01-14
Start date
2002-04-30
Completion date
2016-12-31
Last updated
2015-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult and Pediatric Chronic Cerebral Disorders

Keywords

brain injury, brain disorders

Brief summary

Hypothesis: That HBOT can be toxic in the low-pressure range.

Detailed description

The study is a retrospective review of the author's experience treating chronic brain injury with HBOT, supplemented by cases communicated to the author, who developed untoward effects during or after their HBOT. The object of the study was to affirm or refute the author's general impression that there was an optimal dose of HBOT in chronic brain injury which was lower than the traditional dose applied in chronic non-central nervous system wounding. Furthermore, when this lower dosage range was exceeded and approached the traditional doses for non-CNS wounding oxygen toxicity would result. To address these impressions the study seeks to review the author's medical records and other patient/doctor communications to the author where side effects of HBOT occurred in the treatment of chronic brain injury and abstract signs, symptoms, and the dose of HBOT employed.

Interventions

DRUGHyperbaric oxygen therapy

Total body pressurized oxygen

Sponsors

Harch Hyperbaric Research Foundation
CollaboratorOTHER
Paul G. Harch, M.D.
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Cerebral disorder of greater than one year's duration

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
Oxygen toxicityAfter completion of hyperbaric oxygen therapy

Countries

United States

Contacts

Primary ContactPaul G Harch, M.D.
paulharchmd@gmail.com504-309-4948

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026